FY2024 EPS Estimates for TSE:BHC Increased by Zacks Research

Bausch Health Companies Inc. (TSE:BHC) – Research analysts at Zacks Research lifted their FY2024 earnings estimates for shares of Bausch Health Companies in a research report issued on Tuesday, October 22nd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.98 per share for the year, up from their previous estimate of $4.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.50 EPS, Q1 2025 earnings at $1.12 EPS, Q3 2025 earnings at $1.56 EPS, Q4 2025 earnings at $1.73 EPS, FY2025 earnings at $5.77 EPS, Q1 2026 earnings at $1.50 EPS and Q2 2026 earnings at $1.50 EPS.

Bausch Health Companies (TSE:BHC) last announced its quarterly earnings data on Thursday, August 1st. The company reported C$1.22 earnings per share for the quarter, meeting the consensus estimate of C$1.22. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The firm had revenue of C$3.29 billion during the quarter, compared to analyst estimates of C$3.20 billion.

Other equities analysts also recently issued research reports about the stock. Raymond James raised shares of Bausch Health Companies to a “hold” rating in a report on Wednesday, July 10th. Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th.

Bausch Health Companies Price Performance

Shares of TSE BHC opened at C$11.17 on Thursday. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of 7,583.76. The company has a market capitalization of C$4.10 billion, a price-to-earnings ratio of -6.38, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77. Bausch Health Companies has a twelve month low of C$5.45 and a twelve month high of C$15.43. The business has a 50 day simple moving average of C$9.58 and a 200-day simple moving average of C$9.93.

Insider Buying and Selling

In related news, Senior Officer Seana Lynne Carson sold 13,370 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of C$8.38, for a total transaction of C$112,087.40. Company insiders own 11.28% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.